108 related articles for article (PubMed ID: 11585442)
1. Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
Morimoto H; Ohashi N; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
J Med Chem; 2001 Oct; 44(21):3369-77. PubMed ID: 11585442
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
Morimoto H; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
J Med Chem; 2001 Oct; 44(21):3355-68. PubMed ID: 11585441
[TBL] [Abstract][Full Text] [Related]
3. Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
Kanda Y; Takahashi T; Araki Y; Konoike T; Mihara S; Fujimoto M
Bioorg Med Chem Lett; 2000 Aug; 10(16):1875-8. PubMed ID: 10969989
[TBL] [Abstract][Full Text] [Related]
4. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
Murugesan N; Gu Z; Stein PD; Spergel S; Mathur A; Leith L; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Morrison RA; Webb ML; Moreland S; Barrish JC
J Med Chem; 2000 Aug; 43(16):3111-7. PubMed ID: 10956219
[TBL] [Abstract][Full Text] [Related]
5. Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors.
Wu C; Decker ER; Blok N; Bui H; Chen Q; Raju B; Bourgoyne AR; Knowles V; Biediger RJ; Market RV; Lin S; Dupré B; Kogan TP; Holland GW; Brock TA; Dixon RA
J Med Chem; 1999 Nov; 42(22):4485-99. PubMed ID: 10579813
[TBL] [Abstract][Full Text] [Related]
6. Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.
Morimoto H; Shimadzu H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
Bioorg Med Chem Lett; 2002 Jan; 12(1):81-4. PubMed ID: 11738578
[TBL] [Abstract][Full Text] [Related]
7. Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Sanagi M; Orita M; Nakahara H; Shimaya J; Tsukamoto S; Tanaka A; Yanagisawa I
Bioorg Med Chem; 2001 Nov; 9(11):2955-68. PubMed ID: 11597477
[TBL] [Abstract][Full Text] [Related]
8. Ethenesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tanaka A; Tsukamoto S; Yanagisawa I
Chem Pharm Bull (Tokyo); 2001 May; 49(5):606-12. PubMed ID: 11383615
[TBL] [Abstract][Full Text] [Related]
9. Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.
Murugesan N; Gu Z; Stein PD; Spergel S; Bisaha S; Liu EC; Zhang R; Webb ML; Moreland S; Barrish JC
Bioorg Med Chem Lett; 2002 Feb; 12(4):517-20. PubMed ID: 11844662
[TBL] [Abstract][Full Text] [Related]
10. Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist.
Wu C; Decker ER; Blok N; Li J; Bourgoyne AR; Bui H; Keller KM; Knowles V; Li W; Stavros FD; Holland GW; Brock TA; Dixon RA
J Med Chem; 2001 Apr; 44(8):1211-6. PubMed ID: 11312921
[TBL] [Abstract][Full Text] [Related]
11. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists.
Kanda Y; Kawanishi Y; Oda K; Sakata T; Mihara SI; Asakura K; Kanemasa T; Ninomiya M; Fujimoto M; Konoike T
Bioorg Med Chem; 2001 Apr; 9(4):897-907. PubMed ID: 11354672
[TBL] [Abstract][Full Text] [Related]
13. The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ET(B) receptor.
Chan MF; Kois A; Verner EJ; Raju BG; Castillo RS; Wu C; Okun I; Stavros FD; Balaji VN
Bioorg Med Chem; 1998 Dec; 6(12):2301-16. PubMed ID: 9925292
[TBL] [Abstract][Full Text] [Related]
14. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
[TBL] [Abstract][Full Text] [Related]
15. Bis-sulfonamides as endothelin receptor antagonists.
Boss C; Bolli MH; Weller T; Fischli W; Clozel M
Bioorg Med Chem Lett; 2003 Mar; 13(5):951-4. PubMed ID: 12617928
[TBL] [Abstract][Full Text] [Related]
16. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.
Wu C; Chan MF; Stavros F; Raju B; Okun I; Mong S; Keller KM; Brock T; Kogan TP; Dixon RA
J Med Chem; 1997 May; 40(11):1690-7. PubMed ID: 9171878
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.
Murugesan N; Tellew JE; Gu Z; Kunst BL; Fadnis L; Cornelius LA; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Panchal B; Valentine MT; Chong S; Morrison RA; Carlson KE; Powell JR; Moreland S; Barrish JC; Kowala MC; Macor JE
J Med Chem; 2002 Aug; 45(18):3829-35. PubMed ID: 12190306
[TBL] [Abstract][Full Text] [Related]
18. Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.
Astles PC; Brown TJ; Halley F; Handscombe CM; Harris NV; Majid TN; McCarthy C; McLay IM; Morley A; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 2000 Mar; 43(5):900-10. PubMed ID: 10715156
[TBL] [Abstract][Full Text] [Related]
19. Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
Stein PD; Floyd DM; Bisaha S; Dickey J; Girotra RN; Gougoutas JZ; Kozlowski M; Lee VG; Liu EC; Malley MF
J Med Chem; 1995 Apr; 38(8):1344-54. PubMed ID: 7731020
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of TA-0201, an endothelin receptor antagonist, with recombinant and human prostate endothelin receptors.
Takahashi M; Taniguchi T; Tanaka T; Kanamaru H; Okada K; Muramatsu I
Eur J Pharmacol; 2003 Apr; 467(1-3):185-9. PubMed ID: 12706473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
